Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure
about
Targeting the Innate Immune Response to Improve Cardiac Graft Recovery after Heart Transplantation: Implications for the Donation after Cardiac DeathCrosstalk between the heart and peripheral organs in heart failureTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesTargeting interleukin-1 in heart diseaseCARD9 as a potential target in cardiovascular diseaseInterleukin-1β levels predict long-term mortality and need for heart transplantation in ambulatory patients affected by idiopathic dilated cardiomyopathy.Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.Leukocyte activity in patients with ST-segment elevation acute myocardial infarction treated with anakinraIndependent roles of the priming and the triggering of the NLRP3 inflammasome in the heart.An expanding role for interleukin-1 blockade from gout to cancer.Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse.Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.The Importance of NLRP3 Inflammasome in Heart FailureClinical predictors of response to anakinra in patients with heart failure.Preventing Heart Failure in Inflammatory and Immune DisordersTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases.Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)Interleukin-18 and IL-18 binding protein.Treating inflammation by blocking interleukin-1 in humans.Interleukin-18 mediates interleukin-1-induced cardiac dysfunction.Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.Mechanisms and consequences of inflammatory signaling in the myocardium.Targeting interleukin-1 in heart failure and inflammatory heart disease.Predicting therapeutic response in patients with heart failure: the story of C-reactive protein.Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling.Innate immunity and the failing heart: the cytokine hypothesis revisited.An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.Role of Inflammation in Heart Failure.Interleukin-1 Blockade for the Treatment of Pericarditis.Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study.Lysosomal destabilization activates the NLRP3 inflammasome in human umbilical vein endothelial cells (HUVECs).Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure.Role of cardiac inflammation in right ventricular failure.Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure: Results From REDHART (Recently Decompensated Heart Failure Anakinra Response Trial).Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment.Overview of the IL-1 family in innate inflammation and acquired immunity.Cellular Therapeutics for Heart Failure: Focus on Mesenchymal Stem Cells.Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets.Early cardiac changes induced by a hypercaloric Western-type diet in "subclinical" obesity.Clinical implications of different biomarkers in elderly patients with heart failure.
P2860
Q26744359-376B3C15-D7CA-438D-A431-C548A89B304FQ26766491-54AF96EF-2F2B-452D-812F-C36474F3E281Q26799747-84A8A991-023C-4586-A511-A5E5243041ACQ27009347-E3285F46-A0E1-4CC0-9E25-800E763B0DE5Q28066993-4377A7DD-276D-4142-9971-8A9EDB5259CFQ33648781-AC11CAA5-9119-40D4-8448-4170F7D7E83CQ33801215-A38DEC03-4A91-4CC2-8D7F-EEEECA36C870Q34777497-5AA7D314-AD82-4935-9F29-5B5ACA98BD0FQ35171781-2F9BBA07-0AEB-41C3-90B7-060C7A2DB0B1Q35219001-F274F03C-E7ED-49B4-AED0-14885793133AQ35847003-905B5B3A-753D-4421-BFEA-1D5823A55F21Q35855691-4EA41DB4-35A1-4126-BF4B-78D947E39614Q35891957-C1E9A76C-B69E-47E1-981F-7701B9B7EBE6Q35898868-6FFCD588-B2A9-488C-B9BB-C6D7B34482D0Q35994802-1D1004AF-7115-419D-A3E3-4D212EEE7D76Q36816872-9C6A8FE0-E481-4A4C-89AF-DDDA01383808Q36985609-6168300F-1615-44FC-BA25-012AE6612EE4Q37220336-FE81609C-A716-4327-B067-8CE502A80533Q37636664-82ED2109-FEF5-4E99-BC12-8296E78E167DQ37656103-D9028FA1-B9E2-4026-BE91-25B64DF28B08Q38008700-206D08A6-1D47-4256-B37C-1F253A777DC4Q38044254-58518951-B4AA-47CE-9358-A35BE7734A7BQ38260179-FA2C1702-88B1-457E-BAE3-59775F7273E3Q38314153-EA525748-2658-46D4-BEE8-4ABC7253FA47Q38380871-F96CF6B8-30DA-479A-B5AD-4C2B42C61081Q38393039-6CC35249-C3E2-46AC-8818-498BEF9D9EAEQ39232014-E46E6411-A4B9-453B-BD91-C08F5DA72030Q39255848-A17695D7-8FD6-4045-ADB0-B469D27D244FQ39386445-B3060216-F47A-41F9-929E-6F4F0B97C89EQ40780801-BFB9B4A8-64D5-4F20-8C5B-0998BCA63C73Q41436049-A9EEA521-E1E2-481A-A6B7-3F856578F7E9Q41785739-B242344C-72F8-4AD6-B02D-3AE75A5A4598Q45068688-64B839D3-A77D-4118-9785-FC9DEFF17135Q45073053-BE45ACFB-1D10-4C33-A246-BE98690E77C0Q47144415-81CAD9BC-6D01-46EE-9BA8-5F6B86EA6722Q47285878-7D044013-8179-4972-9846-AA899D6425A7Q47639049-18016C6D-B5E8-4685-BCFA-2CD231CEE9ACQ47756011-77EA3C8F-6FFA-465D-B0F7-3B93850DB5D2Q48255633-0153B84B-7612-4B04-BD82-A364038402D2Q48793728-69F0906F-EA09-4EAD-8900-01ECFC983F76
P2860
Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@ast
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@en
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@nl
type
label
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@ast
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@en
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@nl
prefLabel
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@ast
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@en
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Enhanced interleukin-1 activit ...... ts with systolic heart failure
@en
P2093
Antonio Abbate
Benjamin W Van Tassell
Eleonora Mezzaroma
Ignacio M Seropian
Keyur Shah
Norbert F Voelkel
Tania Azam
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0033438
P407
P577
2012-01-01T00:00:00Z